Sotera Health Company · NASDAQ:SHC

Sotera Health — Q4 2025 Earnings Presentation

24 slides from Sotera Health's earnings presentation, Feb 24, 2026

  1. Slide 1: Fourth-Quarter & Full-Year 2025 Earnings Results

    Safeguarding Global Health® Fourth-Quarter & Full-Year 2025 Earnings Results February 24, 2026 © 2026 Sotera Health Company | All Rights Reserved.

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures

    Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appro

  3. Slide 3: Speakers

    Speakers Michael B. Petras, Jr. Chairman and Chief Executive Officer Jonathan M. Lyons Senior Vice President and Chief Financial Officer © 2026 Sotera Health Company | All Rights Reserved. 2

  4. Slide 4: 2025 Full-Year Highlights

    2025 Full-Year Highlights Performance  Delivered top- & bottom-line growth; marks 20th consecutive year of revenue growth Net Revenues 5.7%; 5.2% CC (1)(2)  Improved Adjusted EBITDA margins by 118 basis points, to 51%, versus 2024  Free Cash Flow of $210M(1)  Strong results from annual customer

  5. Slide 5: Financials

    Financials © 2026 Sotera Health Company | All Rights Reserved. 4

  6. Slide 6: Consolidated Financial Performance

    Consolidated Financial Performance $ In millions, except Adjusted EPS and Adjusted EBITDA margin Fourth Quarter FY 2025 +4.6% / +2.5% CC +5.7% / +5.2% CC $303 $1,164 $290 $1,100 Revenue 2024 2025 2024 2025 +2.7% / 0.5% CC +8.2% / +7.8% CC $157 $594 $153 $549 Adjusted EBITDA 52.7% 51.8% 49.9% 51.0% 2

  7. Slide 7: Sterigenics Financial Performance

    Sterigenics Financial Performance $ In millions Fourth Quarter FY 2025 Revenue +10.6% / +8.0% CC Revenue +8.3% / +7.7% CC Segment Income +10.4% / +7.8% CC Segment Income +9.2% / +8.6% CC $198 $698 $756 $179 $100 $110 $378 $413 55.5% 55.4% 54.2% 54.6% 2024 Revenue Segment Income 2025 2024 Revenue Seg

  8. Slide 8: Nordion Financial Performance

    Nordion Financial Performance $ In millions Fourth Quarter FY 2025 Revenue -12.3% / -12.6% CC Revenue +8.2% / +9.1% CC Segment Income -18.9% / -19.3% CC Segment Income +6.3% / +6.9% CC $57 $188 $50 $173 $35 $108 $29 $101 62.1% 57.5% 58.4% 57.3% 2024 Revenue Segment Income 2025 2024 Revenue Segment I

  9. Slide 9: Nelson Labs Financial Performance

    Nelson Labs Financial Performance $ In millions Fourth Quarter FY 2025 Revenue +2.3% / -0.2% CC Revenue -3.9% / -5.0% CC Segment Income +1.9% / -1.2% CC Segment Income +6.0% / +4.4% CC $54 $55 $229 $220 $18 $18 $69 $73 33.5% 33.4% 30.2% 33.3% 2024 Revenue Segment Income 2025 2024 Revenue Segment Inc

  10. Slide 10: Net Leverage, Liquidity and Investments

    Net Leverage, Liquidity and Investments $ In millions $937 $696 $687 $592 • As of 12/31/25, strong liquidity position of $937M Liquidity $400 $410 $277 $345 • No outstanding borrowings on the revolving line of credit $296 12/31/23 12/31/24 12/31/25 Unrestricted Cash Revolver Availability 3.8x 3.7x 3

  11. Slide 11: 2026 Outlook

    2026 Outlook © 2026 Sotera Health Company | All Rights Reserved. 10

  12. Slide 12: Full-year 2026 Outlook

    Full-year 2026 Outlook (1) FY 2026 Outlook $1,233M to $1,251M Net Revenues +6.0% to 7.5% +5.0 to 6.5% CC $632M to $641M Adjusted EBITDA +6.5% to 8.0% +5.5 to 7.0% CC Interest Expense $135M to $145M Tax Rate Applicable to Adjusted Net Income(2) 27.0% to 29.0% Adjusted EPS $0.93 to $1.01 Weighted Aver

  13. Slide 13: Additional 2026 Outlook Items

    Additional 2026 Outlook Items • Total company pricing expected to be approximately the mid-point of 3% - 4% long-term range General • Foreign exchange benefit expected to be weighted toward 1H ’26, with largest impact expected in Q1’26 Commentary • Net leverage ratio expected to improve versus 12/31

  14. Slide 14: Investor Day Commitments & Corporate Overview

    Investor Day Commitments & Corporate Overview © 2026 Sotera Health Company | All Rights Reserved. 13

  15. Slide 15: Executing Against our Investor Day Commitments

    Executing Against our Investor Day Commitments 2025-2027 FY 2025 Status Target Organic Revenue Growth(1) 5 - 7% 5.2% On track Adjusted EBITDA Growth(1) 5 - 8% 7.8% On track Adjusted EBITDA Margin Improvement 50 - 150bps 118bps On track Cumulative Free Cash Flow $500M - $600M $210M On track Net Lever

  16. Slide 16: Corporate Responsibility Journey Since 2020 IPO

    Corporate Responsibility Journey Since 2020 IPO 2021 2022 2023 2024 2025  Developed corporate  Published Inaugural  Published 2nd Corporate  Published 3rd Corporate  Appointed Lead responsibility strategy Corporate Responsibility Responsibility Report Responsibility Report Independent Director

  17. Slide 17: Our Company Key Priorities

    Our Company Key Priorities 1 2 3 4 Excellence in Win in growth Driving Disciplined serving our markets operational capital customers with excellence to deployment end-to-end enhance free solutions cash flow Strong Execution to Generate Value for Our Stakeholders © 2026 Sotera Health Company | All Ri

  18. Slide 18: Global Leader Positioned for Sustainable Growth

    Global Leader Positioned for Sustainable Growth © 2026 Sotera Health Company | All Rights Reserved. 17

  19. Slide 19: Appendix

    Appendix © 2026 Sotera Health Company | All Rights Reserved. 18

  20. Slide 20: Non-GAAP Financial Measures

    Non-GAAP Financial Measures (unaudited) (dollars in thousands, except per share amounts) Three months ended December 31, Year ended December 31, 2024 2025 2023 2024 2025 Net income $ 12,323 $ 34,847 $ 51,376 $ 44,398 $ 77,949 Amortization of intangible assets 19,640 5,552 81,348 79,377 41,798 Share-

  21. Slide 21: Non-GAAP Financial Measures (continued)

    Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Term Loans

  22. Slide 22: Non-GAAP Financial Measures

    Non-GAAP Financial Measures (unaudited) Year Ended December 31, (in thousands of U.S. dollars) 2025 Net cash provided by operating activities 287,195 Purchases of property, plant and equipment, net (138,018) Other investing activities 2,800 Professional services relating to EO sterilization faciliti

  23. Slide 23: Non-GAAP Financial Measures (continued)

    Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands) As of December 31, 2023 2024 2025 Current portion of long-term debt $ 4,797 14,803 13,973 Long-term debt less current portion 2,223,674 2,208,100 2,126,724 Current portion of finance leases 8,771 2,923 3,465 Finance leases le

  24. Slide 24: Non-GAAP Financial Measures Definitions

    Non-GAAP Financial Measures Definitions • Adjusted Net Income is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period. • Adjusted EBITDA is defined as Adjusted Net Income be

Sotera Health Company — Q4 2025 Earnings Presentation on 6ix